Introduction {#Sec1}
============

Protein S (PS; MIM 176880) is a vitamin K-dependent plasma glycoprotein that functions as a non-enzymatic co-factor of activated protein C (APC) in the proteolytic degradation of activated factor V and activated factor VIII (Dahlbäck [@CR5]; Esmon [@CR12]). Approximately 60% of PS is non-covalently bound to C4b-binding protein (C4BP). The remaining 40% circulates as free PS and represents the biologically active portion of circulating PS (Dahlbäck and Stenflo [@CR6]). It was demonstrated recently that the C4BP-bound PS may play a role in the inactivation of activated factor V (Maurissen et al. [@CR23]).

Inherited PS deficiency is considered to be an autosomal haploinsufficiency disorder that is associated with venous thrombosis. It is generally classified in three categories: (a) type I, characterized by a quantitative deficiency of total and free PS antigen; (b) type II, characterized by a qualitative defect with reduced APC cofactor activity but normal levels of total and free PS antigen; (c) type III, characterized by a quantitative deficiency of free PS antigen only (Bertina [@CR1]).

The precise prevalence of PS deficiency remains unknown because it is quite rare and because a correct diagnosis with plasma assays is complicated. The latter is the result of limitations of the laboratory techniques and of the fact that PS levels are influenced by acquired and hereditary factors, such as age, sex, pregnancy, oral contraceptive use, vitamin K intake and polymorphisms in the PS gene (Persson et al. [@CR24]; Ten Kate and van der Meer [@CR37]). In thrombotic patients, the estimated prevalence of inherited PS deficiency varies from 2--5% in unselected patients to 1--13% in selected patients from thrombophilia families (Lane et al. [@CR21]; Seligsohn and Lubetsky [@CR32]; Ten Kate and van der Meer [@CR37]), while in the general population estimates differ sharply between 0.03 and 0.13% (Dykes et al. [@CR11]).

PS is encoded by *PROS1* which is approximately 80 kb long and consists of 15 exons and 14 introns. *PROS1* is located near the centromere of chromosome 3 at position 3q11.2 (Schmidel et al. [@CR29]). A transcriptionally silent pseudogene (*PROSP*) is located close to *PROS1* and is 95 and 97% similar to *PROS1* for introns and exons, respectively, except for exon 1, which is absent in *PROSP* (Ploos van Amstel et al. [@CR25], [@CR27]). Both the large size of the gene and the presence of the pseudogene complicate the study of *PROS1* mutations.

Screening for *PROS1* mutations has been performed in a number of studies (Espinosa-Parrilla et al. [@CR13]; Gómez et al. [@CR17]; Johansson et al. [@CR20]; Reitsma et al. [@CR28]). Many of these were based on a strategy of resequencing exons and flanking intronic regions. More than 200 different *PROS1* mutations have been described up to now. The vast majority of these are missense or nonsense mutations and only a few are gross deletions or duplications (Gandrille et al. [@CR15]; Stenson et al. [@CR35]; Ten Kate and van der Meer [@CR37]). In type I and III PS deficiency, the mutations are spread throughout *PROS1*, while type II is usually caused by missense mutations in exons 5 and 8, which encode the epidermal growth factor (EGF)-like domains (García de Frutos et al. [@CR16]). Coexistence of type I and III deficiencies in the same family has been described and seems to be explained by the observation that total PS levels increase with age, whereas free PS levels are not influenced by age (Simmonds et al. [@CR34]).

Overall, *PROS1* mutations have been identified in only 50% of the PS deficient families that were analyzed (Johansson et al. [@CR20]; Lanke et al. [@CR22]). The reason for this is poorly understood. Segregation of genetic markers in PS deficient families suggested that mutations should be sought in or close to *PROS1* (Lanke et al. [@CR22]). Since large deletions and duplications are not detected with a PCR-based DNA sequencing approach, other techniques were explored. Using segregation analysis, Johansson et al. indirectly detected large deletions in several mutation-negative patients with PS deficiency (Johansson et al. [@CR20]). Furthermore, three case-reports have been published that used a multiplex ligation-dependent probe amplification analysis (MLPA) which detected two large deletions (Yin et al. [@CR38]; Yoo et al. [@CR39]) and one large duplication (Choung et al. [@CR3]) in patients with PS deficiency. MLPA is a technique that allows the evaluation of multiple fragments from a gene in a single reaction and can detect copy number variation (CNV) involving one or more exons (Schouten et al. [@CR31]).

The aim of this study was to investigate whether large deletions or duplications are common in hereditary PS deficiency and whether MLPA represents a useful screening tool in individuals with point mutation-negative PS deficiency.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

DNA samples were obtained from families or isolated probands who were recruited by a French network which was set up to study PS deficiency. The probands were consecutive patients who were referred to a specialized clinical hematology laboratory because they had at least one episode of thrombosis of unidentified cause. The clinical criteria for including PS deficient thrombotic patients (probands) and the PCR-based DNA resequencing results have been described before in three reports (Borgel et al. [@CR2]; Duchemin et al. [@CR10]; Gandrille et al. [@CR14]). The diagnosis of PS deficiency was based on a total PS level below 65% of normal, as measured with an immunologic assay (Asserachrom Protein S; Diagnostica Stago, Asnières, France), and/or a free PS level below 65% of normal, as measured with the same immunologic assay after precipitation of the C4BP/PS complex with polyethylene glycol (Comp et al. [@CR4]). Sex, age, and pregnancy were not taken into account when assigning a deficiency state. Patients using vitamin K antagonists were excluded from analysis. Patients who were classified as type I or type III PS deficient were asked to provide blood for DNA analysis and a second PS measurement. Only DNA from patients in whom PS deficiency was confirmed by a second assay was analyzed. Family studies were undertaken whenever possible.

For the present study, PS deficient subjects of the French network were selected with a high probability of having a hereditary PS deficiency, either by having a family history of PS deficiency transmission, or by having very low PS measurements. In all of them, no mutation was found by exon-targeted sequencing of *PROS1*. The panel (Table [1](#Tab1){ref-type="table"}) comprised eighteen probands out of which ten were type I and eight were type III PS deficient. Nine were isolated probands and nine were probands with thirty family members including nine non-PS deficient and twenty-one PS deficient subjects. Families 1 and 2 (Gandrille et al. [@CR14]) (Borgel et al. [@CR2]) and families 4 and 8 (Duchemin et al. [@CR10]) were part of previous reports of the French network. All other families and probands were not included in previous publications. PS measurements for the probands are presented in Table [1](#Tab1){ref-type="table"}.Table 1Characteristics of probands with PS deficiency and MLPA resultsFamilyProbandNumber of family member available for analysisTotal PS (%)^a^Free PS (%)^a^PS deficiencyCNV in *PROS1* ^b^ExonsPS deficientNot PS deficient1S1104540Type INot found--2S3035538Type Ic.(210_294)\_(1323_1360)dup4--11^c^3S11005523Type Ic.(697_909)\_(1323_1360)del9--11^d^4S17106322Type Ic.(?\_-133)\_(\*1\_?)delAll5S20115542Type INot found--6S24216620Type IIINot found--7S27501937Type INot found--8S33311815Type Ic.(?\_-133)\_(\*1\_?)del^e^All9S38008431Type IIINot found--10S390013015Type IIINot found--11S40006520Type IIINot found--12S41008015Type IIIc.(210_294)\_(929_1010)del4--9^c^13S42005025Type INot found--14S43007619Type IIINot found--15S44005925Type Ic.(?\_-133)\_(\*1\_?)delAll16S45007245Type IIINot found--17S46305621Type INot found--18S52537113Type IIINot found--^a^Normal PS level: ≥65%^b^NM_000313.2, according to the guidelines of Mutation Nomenclature Homepage at the HGVS website (den Dunnen and Antonarakis [@CR9] at <http://www.hgvs.org/mutnomen> accessed 12 May 2009)^c^The involvement of exon 3 can not be ruled out as there is no probe for this exon in P112 MLPA kit^d^The involvement of exon 8 can not be ruled out as there is no probe for this exon in P112 MLPA kit^e^For this family, qPCR suggests that *GPR15* is also deleted. Therefore, at least 5 Mb upstream from exon 1 of *PROS1* are deleted

MLPA {#Sec4}
----

MLPA was performed as described before (Schouten et al. [@CR31]) using the SALSA MLPA KIT P112 *PROS1* (MRC-Holland, Amsterdam, The Netherlands). Briefly, MLPA is a PCR-based technique for the relative quantification of genomic DNA sequences. The P112 *PROS1* kit contains thirteen probes that target twelve of the fifteen exons of *PROS1*, one probe targeting a segment of DNA which is located 6.5 kb in front of the first exon of *PROS1*, one probe targeting exon 4 of the pseudogene (*PROSP*) and twenty-one control probes targeting different chromosomes (chromosome 1, 2, 3, 5, 7, 9, 10, 12, 14, 15, 16, 18, 19, 21). After amplification, fragments were analyzed on an ABI PRISM^®^ 3730xl Analyzer (Applied Biosystems, Foster City, CA, USA) and the GeneMapper software (Applied Biosystems, Foster City, CA, USA) was used for visualizing peaks and calculating peak areas. Calculation of relative probe signals was adapted from Schouten et al. ([@CR31]) and obtained by dividing the peak area of a given exon probe by the peak area of flanking control probes. The results of test samples were compared to the results of two different pools of control DNA samples that were run concurrently. Deletions and duplications are apparent by a 35--50% variation of relative peak area of the amplification product of a given probe in comparison to the relative peak area of the same probe for the control samples. When a deletion or duplication was suspected, the assay was repeated for confirmation.

Quantitative PCR analysis {#Sec5}
-------------------------

A qPCR analysis was performed for patients that presented with deletions in the MLPA analysis (Hoebeeck et al. [@CR18]; Johansson et al. [@CR20]; Yin et al. [@CR38]). Primers were designed for intron 4, intron 6, and intron 10 of *PROS1*, avoiding concurrent amplification of *PROSP*. For normalization, we designed primers for genes of which the copy number is not known to vary, namely *GPR15*, *ZIC4* (both on chromosome 3) and *PRR15* (on chromosome 7). Primers are described in Table [2](#Tab2){ref-type="table"}. Nine family members with normal values of PS were evaluated as controls. The qPCR was performed using SYBR-Green detector on an ABI Prism 7900HT Fast Real Time PCR system (Applied Biosystems, Foster City, CA, USA). Reaction mixtures contained 1× SYBR-Green^®^ PCR Master Mix (Applied Biosystems, Foster City, CA, USA), 200 nM of each primer and 1 ng/μl of template DNA in a total volume of 25 μl. Samples were analyzed in duplicate and a second run was performed to confirm the results. Cycling conditions were as follows: 10 min on 95°C, 40 cycles consisting of 94°C for 15 s and 60°C for 1 min. Data were analyzed with the ABI Prism 7900 sequence detection system (version 2.2.2; Applied Biosystems, Foster City, CA, USA) and quantified with the comparative threshold cycle method using the genes mentioned above as a reference (de Visser et al. [@CR7]). The fold difference expected for a normal individual with one copy of the gene per haploid is 1. The expected fold difference for an individual with a deletion in one of the chromosomes is 0.5 and the fold difference for an individual with a duplication will be 1.5.Table 2Primers for quantitative PCR techniqueGene productGeneIDForward primerReverse primer*PROS1* intron456275′GTCCCACCAGTTTGGAAGGA5′GCAGGCATCCACTCTGATCTTA*PROS1* intron656275′GGTCCAAAGGCCAATCTGTTAT5′CCCATACCAGCAGACACTACCA*PROS1* intron1056275′GCCATGATGAGGATGTGGATT5′CCACAAAGCCATTAGCTTCTGA*GPR15*28385′CATTGTGACCTGCTACTGTTGCA5′TTTGTTGTGCTTTCCTGATTGC*ZIC4*841075′CGGTTTCCCTGAGTTCTTTTCA5′GCCAGGATTCCAGTGTGACCTA*PRR15*2221715′CCCAGGTGCTTATCCAAAGG5′TGACTGTAGATGGACGCCAAA

Results {#Sec6}
=======

MLPA analysis {#Sec7}
-------------

CNV was detected in six out of eighteen PS deficient probands (Table [1](#Tab1){ref-type="table"}). Of these six individuals five were classified as type I deficient and one as type III deficient. Complete deletion of *PROS1* was detected in three probands with type I deficiency. Two probands appeared to have a partial deletion involving different parts of the gene; one from exon 4 through 9 (type III deficiency) and another from exon 9 through 11 (type I deficiency). In one family with type I deficiency a duplication of at least exon 4 through 11 was detected. Three out of six probands with a CNV had other family members available for analysis and three were isolated probands. In the family members (family 2, 4 and 8) the CNVs were shown to co-segregate with PS deficiency (Fig. [1](#Fig1){ref-type="fig"}). A representative example of how a gene deletion shows up in a MLPA analysis is given in Fig. [2](#Fig2){ref-type="fig"}.Fig. 1Family trees of probands that presented with copy number variation in the MLPA analysis showing co-segregation of deletions/duplications with PS deficiency. *Arrows* indicate probands (*P*). Year of birth (*b.*) is indicated together with sample numberFig. 2Example of a MLPA electropherogram of a patient with a PROS1 deletion (*top*) and a control (*bottom*). Exons peaks are highlighted by *bars* and indicated by their names. *Non-highlighted peaks* correspond to control genes. *x*-axis represents the fragment size in base pair. Note that the height of the exon peaks compared to the flanking control peaks is lower in the patient in comparison to the control. Taking exon 6 as an example, the *arrows* indicate the flanking control genes to which exon 6 is compared. For objective comparison we used the relative peak area, which was calculated by the division of a given exon peak area by the sum of the peak areas of flanking control genes. Variation of more than 35% is considered a deletion (if less) or a duplication (if more)

qPCR analysis {#Sec8}
-------------

As a confirmation tool, qPCR was performed for *PROS1* introns 4, 6 and 10, and three genes elsewhere in the genome were used for normalization. Nine out of ten individuals (five probands and four family members) who showed variation in the MLPA analysis were evaluated. DNA from proband S3, with a putative partial duplication by MLPA analysis, was not available in sufficient quantities for further tests.

We performed analyzes using three different control genes for normalization. When *ZIC4* (on chromosome 3) and *PRR15* (on chromosome 7) were used for normalization, the qPCR confirmed all MLPA results. However, when *GPR15* (chromosome 3) was used as reference gene, one of the families (family 8, samples S33, S34, S36 and S37) presented with a fold change of 1 suggesting that the deletion also involved this control gene. *GPR15* is located on chromosome 3 at location 3q11.2-q13.1, approximately 5 Mb upstream (telomeric) from exon 1 of *PROS1*. Because the qPCR returned a fold change of 0.5 when *ZIC4*, which is far upstream from exon 1 of *PROS1*, and when *PRR15*, which is on chromosome 7, were used for normalization, we conclude that the deletion in this family involves *PROS1* and *GPR15*, including at least 20 confirmed genes in between.

Discussion {#Sec9}
==========

In this study, we evaluated eighteen probands with PS deficiency in whom mutations were not found by exon targeted sequencing. Ten out of eighteen probands were type I deficient and eight were type III deficient. Nine of the probands had family members that could be studied. In six out of eighteen probands (33%) we discovered deletions or duplications in *PROS1* with the MLPA method. Of these six, one had type III deficiency (isolated proband) and the others had type I deficiency (two isolated probands and three probands with family members).

To confirm the deletions found by MLPA, we performed a qPCR analysis using primers that were designed for selected introns and we chose three genes for normalization (*GPR15* and *ZIC4* on chromosome 3 and *PRR15* on chromosome 7). Surprisingly, four members from one of the families possessed a very large deletion that also involved *GPR15*, 5 Mb upstream from exon 1 of *PROS1.* Evidence that *PROS1* deletions might involve nearby genes up to at least 6.5 kb upstream was found before (Johansson et al. [@CR20]; Yin et al. [@CR38]; Yoo et al. [@CR39]), but deletions larger than that were not reported. On the basis of the available data it is not possible to delineate how far the deletion extends beyond *GPR15*, but this result illustrates that some PS deficient families may have quite large deletions of chromosome 3. We do not have access to further clinical information from this family but it is possible that, because the deleted genes are all in a haploinsufficiency state, no other inherited diseases are apparent. It may be worthwhile in the future to evaluate selected PS deficient patients for the presence of other inherited disorders.

Although more than 200 mutations have been described in PS deficient patients, less than 5% are gross deletions or duplications \[Gandrille et al. [@CR15]; Stenson et al. [@CR35] at HGMD (<http://www.hgmd.cf.ac.uk/ac>. Accessed 12 May 2009)\]. Until 2005, only two large deletions were described in *PROS1* (Ploos van Amstel et al. [@CR26]; Schmidel et al. [@CR30]). One of the likely reasons for this is that the detection technique, i.e. Southern blotting, is laborious and time-consuming. Moreover, Southern blots of *PROS1* can not be easily interpreted because of the presence of the PS pseudogene.

Johansson et al. ([@CR20]) found large deletions in three out of eight investigated PS deficient families (38%, all type I and mixed type I/III deficiency), who were *PROS1* mutation-negative, suggesting that CNVs are an important factor in PS deficiency. These authors performed a segregation analysis using a dense set of SNPs and microsatellite markers and this approach proved to be efficient in some families. In other families the markers were not informative, showing the limitations of the use of segregation analysis. Furthermore, *PROS1* is not directly targeted and deletions/duplications of exons that are not covered by the microsatellite markers could easily be missed.

Three recent case-reports document two large deletions and one large duplication in *PROS1* (Choung et al. [@CR3]; Yin et al. [@CR38]; Yoo et al. [@CR39]). In these three studies, MLPA was used to screen for CNVs, underlining the usefulness of this technique for the examination of large gene rearrangements, even in a single patient. In the present study, we provided further evidence that gross CNVs are an important cause of PS deficiency in both families and isolated cases. We found deletions or duplications in 50% of the type I (5 out of 10), and 12.5% of the type III deficient (1 out of 8) point mutation-negative probands, suggesting that gene deletions are less common in type III families. This is, of course, not surprising as type III individuals have (near) normal levels of total PS, which is not easily reconciled with a gene deletion. It is also interesting to note that the only type III deficient patient with a CNV was an isolated proband, which does not exclude that it comes from a family with mixed type I/III deficiency.

The present panel of patients was drawn from a large set of French PS deficient individuals. Eighteen probands with a high probability of having a hereditary PS deficiency were selected. In 33% of the probands we found a CNV, showing that deletions/duplications are common in patients with putative hereditary PS deficiency. However, one should take care in extrapolating those numbers to consecutive patients with PS deficiency. Together, it seems to be worthwhile to include MLPA as a screening tool when investigating the molecular bases of hereditary PS deficiency.

We can only speculate on the reasons why CNVs occur quite frequently in the *PROS1* gene. Out of the five deletions and one duplication, three involved the complete gene, and one of these extends at least 5 Mb to the 5′(telomeric)-direction. Previous studies have also shown large deletions of *PROS1* involving exon 1 and nearby genes (Johansson et al. [@CR20]; Yin et al. [@CR38]; Yoo et al. [@CR39]) which gave rise to the idea that there could be a rearrangement focus somewhere telomeric to the *NSUN3* gene (Yoo et al. [@CR39]), but this claim was never objectively analyzed. In the remaining cases, exons 4, 9, and 11 where always involved. Thus, a hotspot for rearrangement might exist somewhere in these regions of *PROS1*. Further, the first case of PS deficiency due to a translocation \[t(3;21)(q11.2;q22)\] was recently described (Hurtado et al. [@CR19]), reinforcing the idea that the *PROS1* locus may be prone to structural changes. It has been shown that highly homologous low copy repeat structures, as well as AT-rich palindromes and peri-centromeric repeats are located at breakpoints of rearrangement leading to both homologous recombination and non-homologous end joining rearrangements mechanisms (Shaw and Lupski [@CR33]).

Despite that this paper and those that precede it now report that CNVs are quite common in PS deficiency, there remains a large part of PS deficiency with unknown genetic causes. There are several possible reasons for this. First, the MLPA technique that was used did cover most, but still not all of the exons, so it remains possible that small deletions that hit these exons are often present in the remaining cases. The reason that some exons are not covered has to do with interference by the PS pseudogene in the MLPA reactions or with difficulty in examining AT rich regions. Secondly, the promoter region of *PROS1* was only recently characterized and perhaps mutations in this region are quite common. Mutation analysis in the past has only poorly covered this region of the gene (de Wolf et al. [@CR8]; Tatewaki et al. [@CR36]). Thirdly, inversions of parts of the gene can not be ruled out by the MLPA technique as this does not change the copy numbers of the exons. Finally, recombination between gene and pseudogene may go unnoticed with the currently available detection techniques.

In conclusion, this study confirms that gross gene abnormalities in *PROS1* are common in PS deficient patients and it appears that MLPA is a useful tool in direct screening for copy number changes in *PROS1.* The qPCR confirmed the results, which underlines the accuracy of MLPA as a screening tool.
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